InvestSMART

Bio-Gene Technology Ltd (ASX:BGT)

ALERT: Price-sensitive ASX Announcement for BGT
Current share price for BGT : $0.017 -0.016 (-48.48%)+
Announcement
Release
3 Mar 2026 9:05AM
Price at Release
$0.033
Full Release
download
Summary
Bio-Gene Technology Limited is advancing the regulatory development of Flavocide, a novel insecticide, as a new active constituent. The company plans to submit its first application for registration with the Australian Pesticides & Veterinary Medicines Authority (APVMA) by March 2027. The development involves a series of toxicology studies, including reproductive and neurotoxicity studies, designed to meet OECD standards. The primary goal is to secure approval for Flavocide’s use in professional and domestic insecticides, excluding food production. Bio-Gene aims to address global insecticide resistance issues through a new mode of action. Subsequent registration efforts are planned for the USA and other major markets. The regulatory submissions are part of Bio-Gene's strategy to commercialize Flavocide by forming international partnerships and licensing agreements.
Key Points
  • Flavocide development program is progressing with key toxicology studies underway.
  • Initial toxicology results support further studies on reproductive and neurotoxicity.
  • First regulatory submission to APVMA targeted for March 2027.
  • Flavocide aimed at professional and domestic insecticide use, excluding use in food production.
  • Data generated to OECD standards to support global regulatory submissions.
  • Bio-Gene's strategy includes licensing and commercialization through partners.
  • Flavocide's new mode of action addresses insecticide resistance.
  • Future registration planned in the USA and other major markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.